Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119846 · ClinicalTrials.gov registry record · Phase 2
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT01119846 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants.
The verdict
NCT01119846, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.
Interventions
- DRUG Sitagliptin
- DRUG GSK1292263
- DRUG GSK1292263 matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2009-06-05 |
| Est. Completion | 2010-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119846
The ClinicalTrials.gov registry entry for NCT01119846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sitagliptin is the first listed.
NCT01119846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119846 about?
NCT01119846 is a clinical study titled "A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics". The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.
What is the current status of trial NCT01119846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2009-06-05. Estimated completion is 2010-03-19.
What interventions are being tested in trial NCT01119846?
The interventions under investigation include: Sitagliptin (DRUG), GSK1292263 (DRUG), GSK1292263 matching placebo (DRUG).
Who is sponsoring clinical trial NCT01119846?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.